Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Circulation. 2012 Nov 30;127(1):63–73. doi: 10.1161/CIRCULATIONAHA.112.099242

Figure 2.

Figure 2

AMD3100 enhances the mobilization of circulating CXCR4+ MNCs and Sca1/Flk1 positive cells after IR injury. (A–C) Peripheral-blood (PB) levels of (A) MNCs, (B) CXCR4+ MNCs, and (C) sca1+/flk1+ cells were determined in uninjured mice before injection of AMD3100 (125 ug in100 uL saline) and from 1–24 hours afterward. (D–F) PB levels of (D) MNCs, (E) CXCR4+ MNCs, and (F) sca1+/flk1+ cells were determined in mice before IR injury and treatment with AMD3100 or saline and from 1–28 days afterward. MNC levels were measured with a HemaVet hematology system, and the levels of CXCR4+ MNCs and sca1+/flk1+ cells were measured via FACS analyses of MNCs labeled with fluorescent CXCR4 antibodies (CXCR4+ MNCs) or double-labeled with fluorescent Sca1 antibodies and Flk1 antibodies. (G) IR injury was surgically induced in WT mice that had been transplanted with BM from mice with Tie2-regulated GFP expression. Mice were treated with AMD3100 or saline after injury, and the number of GFP+ BM cells was determined 5 days later; scale bar=100 um. #Bonferroni-adjusted P<0.05 and ##Bonferroni-adjusted P<0.01 versus before injection/IR; §Bonferroni-adjusted P<0.05, §§Bonferroni-adjusted P<0.01 and **P<0.01 versus saline. Panels A–C: n=3, Panels D–F: n=3–5 per treatment group at each time point, Panel G: n=8 per treatment group. SEM are too small to be visible graphically for Panel A, Hour 1; Panel B, Hour 1 and Hour 24; Panel E, Before IR, Day 7 (saline), and Day 28; and Panel F, Day 7 (saline) and Day 28.